Michel Revel Buys 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Director Michel Revel bought 54,545 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $2.75 per share, with a total value of $149,998.75. Following the completion of the purchase, the director directly owned 957,530 shares of the company’s stock, valued at $2,633,207.50. This represents a 6.04% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NLS Pharmaceutics Price Performance

NASDAQ:NCEL opened at $4.41 on Friday. NLS Pharmaceutics Ltd. has a 1-year low of $1.83 and a 1-year high of $30.80. The firm has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $4.04.

About NLS Pharmaceutics

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.